Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema

Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema

•VIVID and VISTA studies used 5 initial monthly loading doses of intravitreal aflibercept injection (IVA), and their results led to the approval of IVA for the treatment of diabetic macular edema (DME) by the United States Food and Drug Administration in 2014.•YOSEMITE and RHINE studies used 5 initi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Photodiagnosis and photodynamic therapy 2025-02, Vol.51, p.104484, Article 104484
Hauptverfasser: Leung, Kai Ching Peter, Au, Sunny, Chi Lik
Format: Artikel
Sprache:eng
Schlagworte:
Diabetic retinopathy
drug administration schedule
Intravitreal injections
Laser therapy
Macular edema
ophthalmology
Retina
Vascular endothelial growth factor A
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 104484
container_title Photodiagnosis and photodynamic therapy
container_volume 51
creator Leung, Kai Ching Peter
Au, Sunny, Chi Lik
description •VIVID and VISTA studies used 5 initial monthly loading doses of intravitreal aflibercept injection (IVA), and their results led to the approval of IVA for the treatment of diabetic macular edema (DME) by the United States Food and Drug Administration in 2014.•YOSEMITE and RHINE studies used 5 initial monthly loading doses of IVA in their landmark DME efficacy trials for faricimab.•KESTREL and KITE studies used 5 initial monthly loading doses of IVA in their landmark DME efficacy trials for brolucizumab.
doi_str_mv 10.1016/j.pdpdt.2025.104484
format Article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_proquest_miscellaneous_3156531514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1572100025000146</els_id><doaj_id>oai_doaj_org_article_f404205cc5f248f6a8092ccca17ddabe</doaj_id><sourcerecordid>3156531514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2205-ddf9142570fee4fcddf6922674fb6f9967a9e484b5cdca55fef9e4a6968fc3613</originalsourceid><addsrcrecordid>eNp9UsFu1DAQjRCIlsIXICEfyyGLndhOcuCAFgqVKnGBs-XY49Yrxw52slW_io_gzjd1li0VJy62Z-bNvJnxq6rXjG4YZfLdbjPb2S6bhjYCPZz3_El1yvqurZkYuqf4Fl1TM0rpSfWilB2lLR8of16dtEPPek7FafX7Yyo-XhMfF8h7HQq-yDZNs86-pEiSIylCfQc6kww61LcpB0vSupg0QSEjLLcAEWOWnMuOkji9JWUdl5sM5SYhdPImp3kNBUjQBTJZsM4yQVyIjvZAnPXeH5yBaBf8CNnAvGBgB2bx2INL_yTVUf_6uQdivUZub8ikzRqwO7Aw6ZfVM4dDwKuH-6z6fvHp2_ZLffX18-X2w1VtmoaK2lo3MN6IjjoA7gzacmga2XE3SjcMstMD4D5HYazRQjhwaGs5yN6ZVrL2rLo81rVJ79Sc_aTznUraqz-OlK-VzthdAOU45chpjHAN753UPR0aY4xmnbU4A9Y6P9aac_qxQlnU5IuBEHSEtBbVMiEFHowjtD1CcaWlZHCP1IyqgygUNnMQhTqIQh1FgVlvHgjWcQL7mPNXBQh4fwQArmzvIatiPEQD1mf8A5zJ_5fgHpddz_8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3156531514</pqid></control><display><type>article</type><title>Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema</title><source>DOAJ Directory of Open Access Journals</source><source>Elsevier ScienceDirect Journals</source><creator>Leung, Kai Ching Peter ; Au, Sunny, Chi Lik</creator><creatorcontrib>Leung, Kai Ching Peter ; Au, Sunny, Chi Lik</creatorcontrib><description>•VIVID and VISTA studies used 5 initial monthly loading doses of intravitreal aflibercept injection (IVA), and their results led to the approval of IVA for the treatment of diabetic macular edema (DME) by the United States Food and Drug Administration in 2014.•YOSEMITE and RHINE studies used 5 initial monthly loading doses of IVA in their landmark DME efficacy trials for faricimab.•KESTREL and KITE studies used 5 initial monthly loading doses of IVA in their landmark DME efficacy trials for brolucizumab.</description><identifier>ISSN: 1572-1000</identifier><identifier>ISSN: 1873-1597</identifier><identifier>EISSN: 1873-1597</identifier><identifier>DOI: 10.1016/j.pdpdt.2025.104484</identifier><identifier>PMID: 39818405</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Diabetic retinopathy ; drug administration schedule ; Intravitreal injections ; Laser therapy ; Macular edema ; ophthalmology ; Retina ; Vascular endothelial growth factor A</subject><ispartof>Photodiagnosis and photodynamic therapy, 2025-02, Vol.51, p.104484, Article 104484</ispartof><rights>2025</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2205-ddf9142570fee4fcddf6922674fb6f9967a9e484b5cdca55fef9e4a6968fc3613</cites><orcidid>0000-0002-5849-3317</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1572100025000146$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,2096,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39818405$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leung, Kai Ching Peter</creatorcontrib><creatorcontrib>Au, Sunny, Chi Lik</creatorcontrib><title>Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema</title><title>Photodiagnosis and photodynamic therapy</title><addtitle>Photodiagnosis Photodyn Ther</addtitle><description>•VIVID and VISTA studies used 5 initial monthly loading doses of intravitreal aflibercept injection (IVA), and their results led to the approval of IVA for the treatment of diabetic macular edema (DME) by the United States Food and Drug Administration in 2014.•YOSEMITE and RHINE studies used 5 initial monthly loading doses of IVA in their landmark DME efficacy trials for faricimab.•KESTREL and KITE studies used 5 initial monthly loading doses of IVA in their landmark DME efficacy trials for brolucizumab.</description><subject>Diabetic retinopathy</subject><subject>drug administration schedule</subject><subject>Intravitreal injections</subject><subject>Laser therapy</subject><subject>Macular edema</subject><subject>ophthalmology</subject><subject>Retina</subject><subject>Vascular endothelial growth factor A</subject><issn>1572-1000</issn><issn>1873-1597</issn><issn>1873-1597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9UsFu1DAQjRCIlsIXICEfyyGLndhOcuCAFgqVKnGBs-XY49Yrxw52slW_io_gzjd1li0VJy62Z-bNvJnxq6rXjG4YZfLdbjPb2S6bhjYCPZz3_El1yvqurZkYuqf4Fl1TM0rpSfWilB2lLR8of16dtEPPek7FafX7Yyo-XhMfF8h7HQq-yDZNs86-pEiSIylCfQc6kww61LcpB0vSupg0QSEjLLcAEWOWnMuOkji9JWUdl5sM5SYhdPImp3kNBUjQBTJZsM4yQVyIjvZAnPXeH5yBaBf8CNnAvGBgB2bx2INL_yTVUf_6uQdivUZub8ikzRqwO7Aw6ZfVM4dDwKuH-6z6fvHp2_ZLffX18-X2w1VtmoaK2lo3MN6IjjoA7gzacmga2XE3SjcMstMD4D5HYazRQjhwaGs5yN6ZVrL2rLo81rVJ79Sc_aTznUraqz-OlK-VzthdAOU45chpjHAN753UPR0aY4xmnbU4A9Y6P9aac_qxQlnU5IuBEHSEtBbVMiEFHowjtD1CcaWlZHCP1IyqgygUNnMQhTqIQh1FgVlvHgjWcQL7mPNXBQh4fwQArmzvIatiPEQD1mf8A5zJ_5fgHpddz_8</recordid><startdate>20250201</startdate><enddate>20250201</enddate><creator>Leung, Kai Ching Peter</creator><creator>Au, Sunny, Chi Lik</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5849-3317</orcidid></search><sort><creationdate>20250201</creationdate><title>Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema</title><author>Leung, Kai Ching Peter ; Au, Sunny, Chi Lik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2205-ddf9142570fee4fcddf6922674fb6f9967a9e484b5cdca55fef9e4a6968fc3613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Diabetic retinopathy</topic><topic>drug administration schedule</topic><topic>Intravitreal injections</topic><topic>Laser therapy</topic><topic>Macular edema</topic><topic>ophthalmology</topic><topic>Retina</topic><topic>Vascular endothelial growth factor A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leung, Kai Ching Peter</creatorcontrib><creatorcontrib>Au, Sunny, Chi Lik</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Photodiagnosis and photodynamic therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leung, Kai Ching Peter</au><au>Au, Sunny, Chi Lik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema</atitle><jtitle>Photodiagnosis and photodynamic therapy</jtitle><addtitle>Photodiagnosis Photodyn Ther</addtitle><date>2025-02-01</date><risdate>2025</risdate><volume>51</volume><spage>104484</spage><pages>104484-</pages><artnum>104484</artnum><issn>1572-1000</issn><issn>1873-1597</issn><eissn>1873-1597</eissn><abstract>•VIVID and VISTA studies used 5 initial monthly loading doses of intravitreal aflibercept injection (IVA), and their results led to the approval of IVA for the treatment of diabetic macular edema (DME) by the United States Food and Drug Administration in 2014.•YOSEMITE and RHINE studies used 5 initial monthly loading doses of IVA in their landmark DME efficacy trials for faricimab.•KESTREL and KITE studies used 5 initial monthly loading doses of IVA in their landmark DME efficacy trials for brolucizumab.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39818405</pmid><doi>10.1016/j.pdpdt.2025.104484</doi><orcidid>https://orcid.org/0000-0002-5849-3317</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1572-1000
ispartof Photodiagnosis and photodynamic therapy, 2025-02, Vol.51, p.104484, Article 104484
issn 1572-1000
1873-1597
1873-1597
language eng
recordid cdi_proquest_miscellaneous_3156531514
source DOAJ Directory of Open Access Journals; Elsevier ScienceDirect Journals
subjects Diabetic retinopathy
drug administration schedule
Intravitreal injections
Laser therapy
Macular edema
ophthalmology
Retina
Vascular endothelial growth factor A
title Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A01%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dosing%20intervals%20in%20Comparison%20of%20one-year%20real-world%20outcomes%20between%20red%20(670%20nm)%20subthreshold%20micropulse%20laser%20treatment%20and%20intravitreal%20aflibercept%20injection%20for%20treatment-na%C3%AFve%20diabetic%20macular%20edema&rft.jtitle=Photodiagnosis%20and%20photodynamic%20therapy&rft.au=Leung,%20Kai%20Ching%20Peter&rft.date=2025-02-01&rft.volume=51&rft.spage=104484&rft.pages=104484-&rft.artnum=104484&rft.issn=1572-1000&rft.eissn=1873-1597&rft_id=info:doi/10.1016/j.pdpdt.2025.104484&rft_dat=%3Cproquest_doaj_%3E3156531514%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3156531514&rft_id=info:pmid/39818405&rft_els_id=S1572100025000146&rft_doaj_id=oai_doaj_org_article_f404205cc5f248f6a8092ccca17ddabe&rfr_iscdi=true